Ryan is a Director of Project Management and the Therapeutic Area head of Oncology at Pharm-Olam. As an immunologist by training, he has had the opportunity to see all facets of pharmaceutical development from the bench to the bedside across R&D through Phase III. From a previous appointment to the NIH Biomarker Consortium steering committee for Inflammation and Immunity to awards from the Cancer Research Institute and American Association of Immunologists, he has been fortunate to contribute for over a decade to supporting biomarker and drug development in immuno oncology.
March 11th, 2020
Cohort management is part and parcel of conducting dose-escalation studies, but not all teams effectively manage it. Pharm-Olam is focused on expediting our sponsors’ early phase cycle time in Oncology to enable rapid delivery of a mean tolerated dose (MTD)/recommended Phase 2 dose (RP2D). Thus, tightly orchestrated cohort management strategies that both protect the safety of trial participants and support the capture of the quality data that sponsors need to move to the next stage of development are equally important.